USO 25086

223054 (HS-20093): A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants with Advanced Solid Tumors

Disease Types: Solid Tumors Research

Eligibility Requirements:

Male or female participants at least 18 years of age (≥18 years)
Participants with histologically confirmed advanced/metastatic solid tumors                                                                                                                                                                                                                                                                                                                Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.
Has adequate organ function.

For more information on this trial CLICK HERE .

Available at:

• Norfolk (Brock Cancer Center)